Novartis NVS announced positive top-line results from the late-stage STEER study on experimental candidate intrathecal ...

The firm said it plans to share data with regulatory agencies from the Phase III STEER trial after it met its primary endpoint.

Novartis has reported positive topline outcomes from the Phase III STEER trial of an investigational gene therapy, ...

The phase 3 STEER study enrolled 127 treatment-naïve patients aged 2 to less than 18 years with SMA type 2 who were able to sit but had never walked independently.

Novartis (NVS) said a Phase 3 study of an intrathecal formulation of its gene therapy Zolgensma met its primary endpoint in ...

The Phase III STEER study met its primary endpoint showing an increase from baseline in HFMSE total score in patients with SMA treated with intrathecal onasemnogene abeparvovec (OAV101 IT) OAV101 IT ...

Ma, X. , Yuan, W. and Li, H. (2024) Primary Anaplastic Intraosseous Meningioma: Illustrative Case. Neuroscience and Medicine, ...

Pair saw modest 0.20% gains and positioned itself at 1.0530. Buyers target continues to be the 20-day SMA. Until the short-term SMA isn’t recovered, the outlook will be bearish. The EUR/USD pair ...

Meanwhile, the economy might add 195,000 jobs in November. On the technical side, the EUR/USD price has recovered to retest the 30-SMA resistance after pausing its decline near the 1.0500 key level.

Additionally, GBP/USD was last seen trading slightly above the 100-period Simple Moving Average (SMA) after staying below this level in the second half of the day on Monday. On the upside ...